Idiopathic Pulmonary Fibrosis Clinical Trials

We anticipate a number of observational studies will be developed from the data collected in the IPF-PRO registry. All planned analyses will be performed by the DCRI statistical team. Planning of the analyses will be done as a coordinated effort between the teams at the DCRI and Boehringer Ingelheim (refer ...

Idiopathic Pulmonary Fibrosis Prospective Outcomes Registry

To assess efficacy and safety of concomitant treatment with nintedanib and sildenafil in IPF patients with advanced lung function impairment.

Winthrop University Hospital Clinical Trials Center is seeking volunteers who have been diagnosed with Idiopathic Pulmonary Fibrosis, a condition which decreases lung function. This study is testing an investigational medication to see if it is safe and effective. Eligible participants will receive study related medical care and study medication at ...

To evaluate the change in 6MWD after 8 weeks of treatment with iNO vs. 8 weeks on placebo as measured by 6MWT (6 minute walk test).

DNA is a structure in the body. It contains data about how the body develops and works. Telomeres are found on the end of chromosomes in DNA. Some people with short telomeres or other gene changes can develop diseases of the bone marrow, lung, and liver. Researchers want to see ...

Systemic sclerosis (SSc) is a chronic multisystem autoimmune connective tissue disease for which the etiology remains unknown. The prevalence for SSc is between 19-75 cases per 100,000 and it is more frequent in women, with a peak occurrence in the 4th or 5th decade of life. Morbidity and Mortality in ...

Objective 1: Generation of a common European database and biobank. The existing national programmes to collect data on chILD in three countries (France, Germany, UK) will enable the consortium to swiftly adapt current frameworks to a functionally appropriate pan-European web-based database and biobank. Importantly, compatibility with ongoing United States chILD ...

Objective: Determine whether treatment of perceived stress, anxiety, and depression with anti-depressant therapy improves dyspnea scores, 6-minute walk (6MW) distance and quality of life (QoL) in patients with Chronic Obstructive Pulmonary Disease (COPD) and ILD (Interstitial Lung Disease) undergoing pulmonary rehab. The study is a prospective, randomized, double-blinded, placebo-controlled study ...

Thirty-six (36) male or postmenopausal/surgically sterilized female subjects with IPF who are eligible, will be randomly enrolled in a 2:1 ratio (KD025 to SOC) to one of two treatment groups. Subjects randomized to Treatment Group 1 will receive KD025 400 mg QD orally for 24 weeks. Subjects randomized to Treatment ...